NEW YORK (GenomeWeb News) – Beckman Coulter said yesterday that it has signed an agreement to acquire Lumigen for $185 million.
 
Lumigen, based in Southfield, Mich., provides detection chemistries for clinical diagnostics and life science research. 
 
Beckman Coulter currently uses Lumigen’s proprietary chemiluminescent chemistry for its Access family of immunoassay systems.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.